At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RXRX Recursion Pharmaceuticals, Inc.
Trading 03-26 11:59:41 EDT
3.20
+0.03
+0.79%
High3.26Low3.10Vol5.21M
Open3.10D1 Closing3.17Amplitude5.21%
Mkt Cap1.69BTradable Cap1.33BTotal Shares527.40M
T/O16.65MT/O Rate1.26%Tradable Shares415.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Recursion Pharmaceuticals Names New Chief Medical Officer
TIPRANKS  ·  05:07
Recursion Pharmaceuticals Names New Chief Medical Officer
Recursion Pharmaceuticals director Christopher Gibson drops 40,000 common shares; disposal totals $130,000
Reuters  ·  04:37
Recursion Pharmaceuticals director Christopher Gibson drops 40,000 common shares; disposal totals $130,000
Nvidia-Linked Shares Jump. Nvidia up 2.8%; Applied Digital, Intel, CoreWeave up over 6%; Aeva Tech up 5%; SoundHound AI up 3%
Tiger Newspress  ·  03-25 22:40
Nvidia-Linked Shares Jump. Nvidia up 2.8%; Applied Digital, Intel, CoreWeave up over 6%; Aeva Tech up 5%; SoundHound AI up 3%
BRIEF-Recursion Pharmaceuticals Inc - Appoints Vicki Goodman As Chief Medical Officer Effective April 6, 2026
Reuters  ·  03-25 21:18
BRIEF-Recursion Pharmaceuticals Inc - Appoints Vicki Goodman As Chief Medical Officer Effective April 6, 2026
Recursion names Vicki Goodman chief medical officer effective April 6, 2026; David Mauro exits after about three years
Reuters  ·  03-25 19:59
Recursion names Vicki Goodman chief medical officer effective April 6, 2026; David Mauro exits after about three years
Recursion Pharmaceuticals CFO Ben R Taylor disposes of USD 51,000 in common shares
Reuters  ·  03-19
Recursion Pharmaceuticals CFO Ben R Taylor disposes of USD 51,000 in common shares
Rose the dog might have just heralded the age of programmable medicine - and here are the stocks that benefit
Dow Jones  ·  03-17
Rose the dog might have just heralded the age of programmable medicine - and here are the stocks that benefit
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Q4 Beat And AI Clinical Progress
Simply Wall St.  ·  03-12
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Q4 Beat And AI Clinical Progress
Recursion Pharmaceuticals CEO and President Najat Khan Disposes of Common Shares
Reuters  ·  03-12
Recursion Pharmaceuticals CEO and President Najat Khan Disposes of Common Shares
Insiders Cash Out: GE Vernova, Recursion, Axon, Seagate, Energy Fuels
TIPRANKS  ·  03-07
Insiders Cash Out: GE Vernova, Recursion, Axon, Seagate, Energy Fuels
Recursion Pharmaceuticals’ Earnings Call Highlights AI Momentum
TIPRANKS  ·  03-07
Recursion Pharmaceuticals’ Earnings Call Highlights AI Momentum
Recursion Pharmaceuticals Director Blake Borgeson Disposes of Common Shares
Reuters  ·  03-05
Recursion Pharmaceuticals Director Blake Borgeson Disposes of Common Shares
Stock Track | Recursion Pharmaceuticals Soars 5.08% Intraday Amid Nvidia Concept Stocks Rally
Stock Track  ·  03-04
Stock Track | Recursion Pharmaceuticals Soars 5.08% Intraday Amid Nvidia Concept Stocks Rally
Nvidia Concept Stocks Rally. Nebius Up 9%; Applied Digital And CoreWeave Up 8%; WhiteFiber Up 7%; Core Scientific Up 6%; WeRide And Recursion Up 4%
Tiger Newspress  ·  03-04
Nvidia Concept Stocks Rally. Nebius Up 9%; Applied Digital And CoreWeave Up 8%; WhiteFiber Up 7%; Core Scientific Up 6%; WeRide And Recursion Up 4%
Recursion Pharmaceuticals Publishes 2025 Shareholder Letter
Reuters  ·  02-28
Recursion Pharmaceuticals Publishes 2025 Shareholder Letter
Nvidia-Linked Shares Fall. CoreWeave Plunged over 17%; Nebius Down 8%; APLD Down 5%; Nvidia Down 2.5%
Tiger Newspress  ·  02-27
Nvidia-Linked Shares Fall. CoreWeave Plunged over 17%; Nebius Down 8%; APLD Down 5%; Nvidia Down 2.5%
Recursion Pharmaceuticals Price Target Maintained With a $8.00/Share by Needham
Dow Jones  ·  02-26
Recursion Pharmaceuticals Price Target Maintained With a $8.00/Share by Needham
Recursion Pharmaceuticals price target lowered to $6 from $7 at BofA
TIPRANKS  ·  02-26
Recursion Pharmaceuticals price target lowered to $6 from $7 at BofA
Balanced Risk-Reward Keeps Recursion at Hold as Key Clinical Catalysts Remain Longer-Dated
TIPRANKS  ·  02-26
Balanced Risk-Reward Keeps Recursion at Hold as Key Clinical Catalysts Remain Longer-Dated
Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Penumbra (PEN)
TIPRANKS  ·  02-26
Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Penumbra (PEN)

Introduction

Company Name.
Recursion Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Issue price:
--